

## 2014 Alliance Group Meeting Committee Chair Agenda Form

Committee	LYMPHOMA
Meeting Date / Time	Friday, May 9, 2014, 8:00-11:00 am
Chair(s)	John P. Leonard, MD
Vice Chair(s)	Nancy L. Bartlett, MD Eric D. Hsi, MD

Agenda Item / Talk / Workshop	
Brief Description <i>(where applicable)</i>	Introductory remarks

Agenda Item / Talk / Workshop	
Brief Description <i>(where applicable)</i>	Update from NCL Lymphoma Steering Committee

<b>Title</b>	Overview of NCI LYSC Clinical Trials Planning Meeting
<b>Speaker's Full Name / Credentials</b> (i.e., Jane Doe, MPH, MD)	John P. Leonard, MD
For non-Alliance speakers, include speaker's professional title, institution or organization, phone # and email address.	

Agenda Item / Talk / Workshop	
Brief Description <i>(where applicable)</i>	Adolescent and Young Adult (AYA) Lymphoma

<b>Title</b>	AYA lymphoma within the cooperative group setting: opportunities and future directions
<b>Speaker's Full Name / Credentials</b> (i.e., Jane Doe, MPH, MD)	Tara Henderson, MD
For non-Alliance speakers, include speaker's professional title, institution or organization, phone # and email address.	

## 2014 Alliance Group Meeting Committee Chair Agenda Form

Agenda Item / Talk / Workshop	
Brief Description (where applicable)	Lymphoma biology update

<b>Title</b>	Review of Alliance lymphoma translational initiatives and specimen bank resources
<b>Speaker's Full Name / Credentials</b> (i.e., Jane Doe, MPH, MD)	Eric Hsi, MD
For non-Alliance speakers, include speaker's professional title, institution or organization, phone # and email address.	

Protocol Review				
Category	Study Title	Study Number	Study Chair	Presenter's Name
<b>In Development</b>	Ibrutinib with AuSCT in relapsed non-germinal center DLBCL	A051301	C. Andreadis	
<b>In Development</b>	Phase III study of ABVD vs AAVD (with brentuximab Vedotin) in stage I/II Hodgkin lymphoma	A051305	N. Wagner-Johnston	
<b>In Development</b>	A randomized phase II trial of rituximab, lenalidomide and ibrutinib vs. rituximab, bendamustine and ibrutinib in patients ≤ 65 years of age with previously untreated mantle cell lymphoma (MCL)	A051306	K. Maddocks	
<b>Active</b>	Phase II trial of response-adapted therapy based on PET in bulky stage I/II Hodgkin lymphoma	50801	A.LaCasce	
<b>Active</b>	Randomized phase II of ofatumumab/bendamustine vs ofatumumab/bortezomib/bendamustine in untreated FL	50904	K. Blum	
<b>Active</b>	Phase I study of rituximab, lenalidomide and ibrutinib in untreated follicular lymphoma	A51103	C. Ujjani	

## 2014 Alliance Group Meeting Committee Chair Agenda Form

<b>Active</b>	Phase I trial of rituximab, lenalidomide and idelalisib in recurrent follicular lymphoma	A051202	J. Leonard	
<b>Active</b>	Phase I/randomized phase II trial of rituximab, lenalidomide and idelalisib in recurrent mantle cell lymphoma	A051201	S. Smith	
<b>Active</b>	E1411: Intergroup randomized ph II 4 arm study in pts >= 60 w/ previously untreated MCL	CTSU	P. Martin	
<b>Active</b>	Myeloablative vs non-myeloablative consolidation chemotherapy for frontline CNS B cell lymphoma	51101	T. Batchelor	
<b>Active</b>	NCIMET 9177: Ph II Study EPOCH +/- Rituximab in Untreated C-Myc+ DLBCL	CTSU	B. Link	
<b>Active</b>	S1001: Ph II PET-directed therapy for limited stage DLBCL	CTSU	S. Park	
<b>Active</b>	E1412: Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma	CTSU	K. Richards	
<b>Active</b>	A Phase I and Feasibility Study of Everolimus (RAD001) plus R-CHOP for Untreated DLBCL	N1085	P. Johnston	
<b>Active, Completed Accrual</b>	Phase III randomized trial of R-CHOP vs R-EPOCH with molecular profiling in untreated DLBCL	50303	W. Wilson/A. Zelenetz	
<b>Active, Completed Accrual</b>	Phase II trial of ofatumumab in untreated follicular lymphoma	50901	C. Rosenbaum	
<b>Active, Completed Accrual</b>	R-HyperCVAD or R-Bendamustine followed by autologous SCT in patients <= age 65	S1106	T. Shea	
<b>Active, Completed Accrual</b>	Phase II Trial of the Aurora Kinase A Inhibitor, MLN8237, in Peripheral T-Cell Non-Hodgkin Lymphoma	S1108	S. Horwitz	